Home > Treatment Options > Tumor Suppressors > Clinical Trials >
Hydroxycarbamide (Siklos®) or (Hydrea)
Last Updated: 12/15/24
Status: Reintroduced Tumor drug treatment for MeningiomaNF2
Index
- Trials
- Other Uses
"Hydroxyurea is an antimetabolite that slows the reproduction of cells, treating certain types of leukemias. It can also help manage sickle cell anemia by increasing the production of other types of hemoglobin and changing how red blood cells stick together. You may buy Hydroxyurea from CareFirst Specialty Pharmacy with a valid prescription from your prescriber."(1)
| Other Names | Hydroxyurea, Hydroxycarbamide, Hydrea, N-Hydroxyurea, Litalir, Oxyurea, Onco-carbide, Biosupressin, Droxia, Hidrix |
|---|---|
| Trade Name | Hydrea™ Droxia™, Apo-Hydroxyurea™ and Gen-Hydroxyurea™, |
| Treatment By | Pill - Oral |
| Inhibitor | An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. |
| Molecular Formula | CH4N2O2 |
|---|---|
| IUPAC | hydroxyurea |
| ChemSpider | 3530 |
| PubChem | CID 3657 |
Trial
- "Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent MG" - www.ClinicalTrials.gov
- "Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (PV)" - www.ClinicalTrials.gov
- "Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG" - www.ClinicalTrials.gov
- "Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma" - www.ClinicalTrials.gov
Other Uses
- Myeloproliferative disease
- Sickle-cell disease
- AIDS
- Second line treatment for psoriasis
- Systemic mastocytosis
- Chronic myelogenous leukemia (replaced by imatinib
- Biochemical research as a DNA replication inhibitor
